To update the FDA label for axicabtagene ciloleucel (Yescarta) to include patients with primary central nervous system lymphoma (PCNSL).
Key Findings:
The FDA label update removes the exclusion for patients with primary CNS lymphoma from receiving CAR T-cell therapy.
Approximately half of treated patients were alive and without relapse at around one year post-treatment.
Interpretation:
The label update significantly expands treatment options for patients with relapsed or refractory PCNSL, allowing access to CAR T-cell therapy that was previously unavailable.
Limitations:
The study involved a small sample size of 18 patients.
Longer follow-up is needed to determine the potential for long-term remission and to monitor for late relapses.
Conclusion:
The FDA's label update, driven by Dana-Farber's research, represents a critical advancement in treatment options for patients with CNS lymphoma.
